A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

NCT00885508 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia

Interventions

DRUG: Lenalidomide

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]